BACKGROUND: We sought to use data captured in the electronic health record (EHR) to develop and validate a prediction rule for virologic failure among patients being treated for infection with human immunodeficiency virus (HIV). METHODS: We used EHRs at 2 Boston tertiary care hospitals, Massachusetts General Hospital and Brigham and Women's Hospital, to identify HIV-infected patients who were virologically suppressed (HIV RNA level < or = 400 copies/mL) on antiretroviral therapy (ART) during the period from 1 January 2005 through 31 December 2006. We used a multivariable logistic model with data from Massachusetts General Hospital to derive a 1-year virologic failure prediction rule. The model was validated using data from Brigham and Women's Hospital.We then simplified the scoring scheme to develop a clinical prediction rule. RESULTS: The 1-year virologic failure prediction model, using data from 712 patients from Massachusetts General Hospital, demonstrated good discrimination (C statistic, 0.78) and calibration (chi(2)= 6.6; P= .58). The validation model, based on 362 patients from Brigham and Women's Hospital, also showed good discrimination (C statistic, 0.79) and calibration (chi(2)= 1.9; P= .93). The clinical prediction rule included 7 predictors (suboptimal adherence, CD4 cell count < 100 cells/microL, drug and/or alcohol abuse, highly ART experienced, missed > or = 1 appointment, prior virologic failure, and suppressed < or = 12 months) and appropriately stratified patients in the validation data set into low-, medium-, and high-risk groups, with 1-year virologic failure rates of 3.0%, 13.0%, and 28.6%, respectively. CONCLUSIONS: A risk score based on 7 variables available in the EHR predicts HIV virologic failure at 1 year and could be used for targeted interventions to improve outcomes in HIV infection.
BACKGROUND: We sought to use data captured in the electronic health record (EHR) to develop and validate a prediction rule for virologic failure among patients being treated for infection with human immunodeficiency virus (HIV). METHODS: We used EHRs at 2 Boston tertiary care hospitals, Massachusetts General Hospital and Brigham and Women's Hospital, to identify HIV-infectedpatients who were virologically suppressed (HIV RNA level < or = 400 copies/mL) on antiretroviral therapy (ART) during the period from 1 January 2005 through 31 December 2006. We used a multivariable logistic model with data from Massachusetts General Hospital to derive a 1-year virologic failure prediction rule. The model was validated using data from Brigham and Women's Hospital.We then simplified the scoring scheme to develop a clinical prediction rule. RESULTS: The 1-year virologic failure prediction model, using data from 712 patients from Massachusetts General Hospital, demonstrated good discrimination (C statistic, 0.78) and calibration (chi(2)= 6.6; P= .58). The validation model, based on 362 patients from Brigham and Women's Hospital, also showed good discrimination (C statistic, 0.79) and calibration (chi(2)= 1.9; P= .93). The clinical prediction rule included 7 predictors (suboptimal adherence, CD4 cell count < 100 cells/microL, drug and/or alcohol abuse, highly ART experienced, missed > or = 1 appointment, prior virologic failure, and suppressed < or = 12 months) and appropriately stratified patients in the validation data set into low-, medium-, and high-risk groups, with 1-year virologic failure rates of 3.0%, 13.0%, and 28.6%, respectively. CONCLUSIONS: A risk score based on 7 variables available in the EHR predicts HIV virologic failure at 1 year and could be used for targeted interventions to improve outcomes in HIV infection.
Authors: Andrea A Howard; Julia H Arnsten; Yungtai Lo; David Vlahov; Josiah D Rich; Paula Schuman; Valerie E Stone; Dawn K Smith; Ellie E Schoenbaum Journal: AIDS Date: 2002-11-08 Impact factor: 4.177
Authors: L C Walter; R J Brand; S R Counsell; R M Palmer; C S Landefeld; R H Fortinsky; K E Covinsky Journal: JAMA Date: 2001-06-20 Impact factor: 56.272
Authors: Matthias Egger; Margaret May; Geneviève Chêne; Andrew N Phillips; Bruno Ledergerber; François Dabis; Dominique Costagliola; Antonella D'Arminio Monforte; Frank de Wolf; Peter Reiss; Jens D Lundgren; Amy C Justice; Schlomo Staszewski; Catherine Leport; Robert S Hogg; Caroline A Sabin; M John Gill; Bernd Salzberger; Jonathan A C Sterne Journal: Lancet Date: 2002-07-13 Impact factor: 79.321
Authors: Joseph Conigliaro; Adam J Gordon; Kathleen A McGinnis; Linda Rabeneck; Amy C Justice Journal: J Acquir Immune Defic Syndr Date: 2003-08-01 Impact factor: 3.731
Authors: Amanda Mocroft; Lidia Ruiz; Peter Reiss; Bruno Ledergerber; Christine Katlama; Adriano Lazzarin; Frank-Detlef Goebel; Andrew N Phillips; Bonaventura Clotet; Jens D Lundgren Journal: AIDS Date: 2003-08-15 Impact factor: 4.177
Authors: Michael J Mugavero; K Rivet Amico; Andrew O Westfall; Heidi M Crane; Anne Zinski; James H Willig; Julia C Dombrowski; Wynne E Norton; James L Raper; Mari M Kitahata; Michael S Saag Journal: J Acquir Immune Defic Syndr Date: 2012-01-01 Impact factor: 3.731
Authors: Merhawi T Gebrezgi; Kristopher P Fennie; Diana M Sheehan; Boubakari Ibrahimou; Sandra G Jones; Petra Brock; Robert A Ladner; Mary Jo Trepka Journal: AIDS Patient Care STDS Date: 2020-04 Impact factor: 5.078
Authors: Chanelle J Howe; Stephen R Cole; Sonia Napravnik; Jay S Kaufman; Adaora A Adimora; Beth Elston; Joseph J Eron; Michael J Mugavero Journal: AIDS Res Hum Retroviruses Date: 2014-01-20 Impact factor: 2.205
Authors: Chanelle J Howe; Sonia Napravnik; Stephen R Cole; Jay S Kaufman; Adaora A Adimora; Beth Elston; Joseph J Eron; Michael J Mugavero Journal: Am J Epidemiol Date: 2014-05-08 Impact factor: 4.897